Paul Pennock is widely considered one of the best and most aggressive plaintiff litigators in the country. His work has led to more than a billion dollars in recoveries for his clients.

Pennock is the Managing Partner of the Mass Tort Litigation Practice Group at Morgan & Morgan, P.A. where he is responsible for leading a large national litigation department covering all aspects of litigation, from inception through trial. He has served as lead plaintiffs’ counsel, plaintiffs’ executive and steering committee member, and liaison counsel in numerous state and federal multidistrict litigation (MDL) mass tort cases, including co-lead of the Seroquel, Actos, Power Morcellator, Elmiron, and Gardasil MDLs and has served as Co-Chair of the Executive Committee for the PPI MDL and on the Executive Committee and steering committee of many others. Most recently, Pennock was named co-lead counsel of the GLP-1 RA MDL.

Pennock has represented plaintiffs in pharmaceutical and/or medical device litigation for several decades. He has also handled numerous bellwether trials and Daubert hearings on expert witness testimony in both state and federal courts. In 2015, he was named national co-lead counsel of the federal power morcellator MDL, where he organized the first majority-women plaintiff steering committee in the 47-year history of multidistrict litigation.

As a well-respected member of the bar, he has been invited to speak at dozens of legal conferences around the country, as well as at several law schools, including Yale, Brooklyn, and the University of Denver, among others.

In 2007, he authored the mass tort litigation chapter in a two-volume legal treatise, The Plaintiff’s Personal Injury Action in New York State, edited by Patrick J. Higgins and published by the New York State Bar Association.

He previously received the coveted Clarence Darrow Award, which recognizes dedication and excellence in the legal profession and is given to attorneys who have demonstrated exceptional conviction in their work.

Morgan & Morgan